NCT04721301View on ClinicalTrials.gov

Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

January 15, 2017

Primary Completion Date

March 15, 2023

Study Completion Date

March 15, 2023

Conditions
Colorectal Cancer MetastaticPancreatic Cancer Metastatic
Interventions
COMBINATION_PRODUCT

Nivolumab plus Ipilimumab plus Maraviroc

In the single treatment arm, all patients receive Nivolumab, Ipilimumab and Maraviroc

Trial Locations (1)

69120

University of Heidelberg / NCT, Heidelberg

All Listed Sponsors
collaborator

German Cancer Research Center

OTHER

lead

University Hospital Heidelberg

OTHER

NCT04721301 - Ipilimumab, Maraviroc and Nivolumab in Advanced Metastatic Colorectal and Pancreatic Cancer the LUMINESCENCE Trial | Biotech Hunter | Biotech Hunter